Corporate Social Responsibility Report

Overview

The report describes Fosun Pharma's continued innovation in healthcare, including the global impact of its artemisinin-based malaria medicines, which had saved 7 million lives of severe malaria patients. It reports 2015 consolidated revenue of RMB12,608.6483 million and continued investment in R&D. The report also highlights strengthened Group-wide EHS management and environmental protection measures. Employee development, stakeholder engagement and community charity are covered throughout the report.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2015
Period: 1 January 2015 – 31 December 2015
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services